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Abstract 
Background: Drug-related problems are prevalent among older patients, and substantially increase the risk of mor-
bidity, (re-)hospitalisation and mortality. To detect drug-related problems and optimize treatment primary caregivers 
should periodically review the medication of older patients. The aim was to develop a structured, comprehensive 
but practicable tool to facilitate and support the reviewing of medication of older patients with a chronic disease by 
pharmacists and general practitioners.
Methods: A tool facilitating clinical medication review by community pharmacists was developed on the basis of 
treatment guidelines, literature data on drug-related problems. For the identification of drug-related problems from 
the patient’s perspective, a script for structured interviews was developed. The tool was optimized by means of a 
Delphi method with an expert panel and testing in a trial.
Results: The medication review tool consists of a comprehensive checklist of 124 drug-related problems divided by 
20 sections according to physiological systems and diseases, and includes a structured interview script for a patient 
interviews.
Conclusion: A structured, comprehensive and practical tool to assist pharmacists and general practitioners to 
perform clinical medication review including a list of potential drug-related problems in older patients with chronic 
disease, as well as a script for structured patient interviews, was developed.
Keywords: Drug-related problems, Potentially inappropriate medicine, Medication review, Tool, Community 
pharmacy, General practice, Patients experience
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Background
Drug-related problems (DRPs) are events or circumstances 
related to drug therapy that actually or potentially inter-
fere with desired health outcomes [1–3]. DRPs are preva-
lent among older patients and substantially increase the 
risk of morbidity, (re-) hospitalization and mortality [4, 5]. 
DRPs include ineffectiveness of treatment, occurrence of 
adverse reactions and dissatisfaction of patients with their 
therapies [3]. DRPs may be the result of a wide variety of 
causes including medication errors, frequent medication 
changes, specific drug effects and drug combinations, 
inappropriate use of medicines, inappropriately prescribed 
medicines, and non-adherence to treatment [3, 6]. Factors 
increasing the risk of DRPs are advanced age, comorbidity, 
polypharmacy and a lack of coordination between differ-
ent caregivers after having initiated, altered or discontin-
ued treatments [6].  Over the years, substantial effort has 
been made to prevent and detect potentially inappropriate 
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medicines (PIM) [6, 7]. Several sets of explicit criteria, of 
which the Beers criteria are the oldest and best known, 
have been developed to assist caregivers in making appro-
priate drug choices or assessing the quality of medication 
[6–8]. Explicit criteria, occasionally combined with other 
measures, are also used as tools to conduct medication 
reviews [9]. Since their introduction in 1991, the Beers cri-
teria, and subsequently adapted sets (STOPP/START cri-
teria) in various countries have been revised and refined 
with respect to structure and comprehensiveness [7, 10]. 
In order to detect DRPs and optimize treatment, primary 
caregivers should periodically review the medication of 
older patients with chronic diseases [6, 11–14]. Being the 
most comprehensive form of medication review [15], a 
clinical medication review (CMR) is a structured, critical 
examination of a patient’s medications. Its objective is to 
reach an agreement with the patient about treatment, opti-
mizing the impact of medicines, minimizing the number 
of DRPs and reducing waste [12–16].
Although a review of medication records solely on the 
basis of explicit criteria may be useful, the result in terms 
of detected DRPs will be of limited value since medical 
status, clinical parameters and the way patients experi-
ence their treatment have not been considered [11, 13, 
15, 17]. Therefore, only a medication review with direct 
input from the patient, addressing perceptions of con-
venience and effectiveness of treatment and eventual dis-
comfort due to adverse events. In this way, treatment can 
be continued in an effective, satisfactory and safe manner 
[11, 15, 17, 18]. This more clinical approach to the medi-
cation review, however, requires expert judgement and is 
likely to be time consuming [6, 13]. Due to its compre-
hensive nature, the large input of data and involvement 
of the general practitioner (GP), pharmacist and patient, 
the review process must be highly structured in order to 
be both cost-effective and practicable [11, 13]. The avail-
ability of a tool to be used for the gathering of medication 
data and DRPs and their evaluation within the framework 
of a CMR process essentially similar to that described and 
used by Lowe and colleagues, would be very helpful in 
implementing CMR in daily practice [12, 15]. The aim of 
the present study was therefore to develop a structured, 
comprehensive, but practicable tool to facilitate and sup-
port the periodic review of older patients’ medication by 
community pharmacists and GPs. The tool accounts for 
the perspective of the patient.
Methods
The present medication review tool is focused on the 
most commonly occurring chronic diseases in older per-
sons, 65 years or older, in the Netherlands as listed by the 
National Institute for Public Health and Environment 
[19] and the medicines most frequently used to treat 
these disorders as listed each year by the Dutch Founda-
tion form Pharmaceutical Statistics [20].
In the Netherlands, in primary care older patients with 
a chronic disease are generally treated according to the 
recommendations of the Dutch GP treatment guidelines 
[21].
With respect to criteria for appropriate prescribing and 
the design and implementation of a CMR, PubMed and 
the Cochrane library were searched using the following 
search terms: ‘development’, ‘tools’, ‘method’, ‘medica-
tion review’, ‘clinical medication review’, ‘drug-related 
problems’, ‘inappropriate medicines’, ‘inappropriate pre-
scribing’, ‘explicit criteria’, ‘adverse effect’, ‘side effect’, 
‘drug–drug interaction’ and ‘older patients’. Only full-text 
papers in English and Dutch up to December 2012 were 
included. Reference lists of identified research papers 
were also checked.
On the basis of the references and literature data and 
their clinical experience two authors in their capacity as 
community-pharmacist/clinical pharmacologist (JGH) 
and clinical pharmacologist/GP (PE) compiled a long-
list of frequently occurring DRPs in older patients with a 
chronic disease. Medication recommended by the Dutch 
GP (NHG) treatment guidelines was considered appro-
priate, deviations were considered inappropriate. DRPs 
definitions were extracted from the PCNE DRP classifi-
cation document (version 6.2) [3]. The PCNE classifica-
tion and the list of patient-related DRPs compiled by De 
Smet et al. [11] were used to formulate a number of ques-
tions related to patient perceptions of drug treatment. 
Questions were organized in the form of a script for a 
structured patient interview. Data gathered during the 
interviews should be used to complete the DRP check-
list. Results of studies on the occurrence of DRPs in older 
patients were used to check the DRP checklist [5, 22–25].
The CMR tool consisting of a DRP checklist and inter-
view script was optimized stepwise by means of a Delphi 
procedure of two rounds with a panel of eleven experts 
in the field and actual testing. The experts in the field 
included (clinical) pharmacists, clinical pharmacolo-
gists, geriatricians and GPs with cardiovascular, asthma/
COPD, diabetes or osteoporosis expertise. The panel was 
asked to comment on the longlist and interview script. 
Panel members were invited to add, change or delete 
items if they felt it necessary. All changes proposed 
were discussed by the authors. If the majority thought a 
change would be useful, the change was made definitive.
The CMR tool was used in a randomized controlled 
trial to evaluate the effect of a CMR and patient coun-
selling on DRPs and compliance after hospital discharge 
[26, 27]. Using medication records, medical and patient 
data, the tool was manually applied in this study. On the 
basis of trial experiences the tool was re-evaluated with 
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the authors of this study and several suggestions for 
improvement were put forward. Subsequently, in the sec-
ond Delphi round, the members of the expert panel were 
asked to comment on the resulting tool in a similar fash-
ion to the first Delphi round.
Ethics
Approval of an ethics committee is not applicable.
Results
The CMR tool comprises a comprehensive checklist of 
drug and patient related DRPs and a script for structured 
patient interviews aimed at identifying DRPs related 
to patient experiences with drug treatment for chronic 
diseases.
The checklist
The checklist consisted of domains. Of the ten most 
frequently occurring chronic disorders in Dutch older 
patients visual disturbances (nr. 1) and deafness (nr. 5) 
were excluded. Since cancer treatment is given predomi-
nantly to hospitalized patients or is hospital-directed, 
DRPs directly related to anti-cancer treatment were also 
excluded. Based on the remaining seven chronic dis-
eases, the medicines most frequently used to treat these 
disorders and a number of patient-related issues related 
to the physiological system were included. Domains 
were ordered into 20 sections. DRPs cover both PIM and 
omissions of potentially beneficial pharmacotherapy. 
Where appropriate, DRPs also relate to laboratory values 
including glucose and HbA1c levels, blood pressure and 
lipoprotein levels.
The resulting tool consisted of a longlist consisting of 
76 DRPs. After the first Delphi round, the list increased 
to 126 DRPs. Examples of DRPs that were added were: 
‘use of high dose of metformin and modification of diet 
in renal diseases (MDRD) <30  mL/min’ and ‘no antihy-
pertensive medication in the presence of micro-vascular 
complications’.
After this Delphi round the tool was used in a ran-
domised controlled trial with 340 older patients dis-
charged from the hospital [26].
In the second Delphi round, three DRPs were deleted 
from the longlist and one DRP was added. The final list 
consisted of 124 DRPs ordered into 11 domains and 20 
sections (Additional file 1: Appendix S1).
The interview script
The interview script consisted of five sections includ-
ing 34 questions addressing items such as the perceived 
effectiveness of medicines, side effects, problems with the 
taking of medicines and problems with respect to adher-
ence (Additional file 2: Appendix S2).
Discussion
The present study concerns the development of a struc-
tured and comprehensive tool to facilitate and support 
(community) pharmacists in conducting a CMR of older 
patients with chronic diseases in close co-operation with 
the patient’s GP. The CMR tool consists of a checklist of 
124 common DRPs and a script for structured patient 
interviews used for the identification of patient-related 
DRPs.
In addition to several drugs-to-avoid and criteria 
addressing omissions of potentially beneficial medicines, 
the present structured list of DRPs includes important 
drug–drug and drug-disease interactions, dosing issues 
and duplicate prescriptions. With respect to these drug 
and disease-related items there is overlap with existing 
lists of explicit criteria developed to identify PIM like 
the Beers list, STOPP/START and the PRISCUS criteria. 
However, the Amsterdam Tool differs from these instru-
ments (with the exception of STOPP/START) by being 
based on DRPs rather than on drugs and diseases and by 
containing criteria of medicine use based on laboratory 
values. However, most importantly the tool addresses 
DRPs from the patient’s perspective. Lists of explicit 
criteria have not been developed as instruments to sup-
port caregivers in conducting a CMR. Nevertheless, in 
the Netherlands, a Multidisciplinary Guideline for Poly-
pharmacy (MDG) has recently been developed [12]. As 
an elaboration of the MDG for polypharmacy, STOPP/
START criteria were recently translated into Dutch and 
supplemented by a step-by-step procedure for the per-
formance of a CMR under the name ‘STRIP method’ 
[12, 28]. The ‘Amsterdam Tool for Clinical Medication 
Review’ can be used as an supplement to these and other 
methods for medication review. Many older patients 
with a chronic disease require specialist treatment and 
their hospitalization rate is well above average [6]. How-
ever, care is predominantly provided by GPs whereas 
medicines are supplied by community pharmacists. In 
the Netherlands, most patients obtain their medicines 
from the same pharmacy [6, 29]. Electronic pharmacy 
medication records (PMR) are therefore fairly complete 
and usually also include data on hospital prescriptions 
[29].
The PMR are therefore an excellent starting point for 
a CMR and the data contained therein are the main sub-
strate for checking for DRPs and the subsequent evalu-
ation. PMR, however, must be combined with medical 
record data provided by the GP [12]. However, in spite 
of the considerable amount of expert knowledge already 
present, additional training with respect to (geriatric) 
pharmacotherapy and improvement of communication 
skills in order to conduct structured patient interviews 
may be required. In this respect studies in Finland and 
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New Zealand suggested that health care professionals did 
not possess the competences to conduct a CMR [16, 30].
A strength of the screening of medication using explicit 
criteria in the form of the CMR tool is a process that 
takes relatively little time to perform. On the other hand, 
the patient interview required to obtain information on 
DRPs from the patient’s perspective, the evaluation of the 
medication data and patient experiences in collaboration 
with the GP and the subsequent transfer of information 
to the patient and counselling are time consuming. Time 
consumption is also highly variable since it depends on 
wide variety of patient-related factors. Any measure to 
make a CMR more time efficient is therefore extremely 
useful.
Using the structured interview script will also increase 
the quality of the initial interview with the patient. The 
present tool is therefore an important contribution in 
terms of enhancing the efficiency of the CMR process 
and makes it more applicable in practice. The Amster-
dam Tool for Medication Review has been used in a ran-
domized controlled study of the effect of a CMR on the 
incidence of DRPs among 340 older patients discharged 
from the hospital [26]. In this study, the CMR resulted in 
a significant reduction in DRPs among patients. In par-
ticular, the DRPs ‘no drug but clear indication’ and ‘fear 
for side effects’ were significantly reduced. Subgroup 
analyses showed that the reduction of DRPs identified 
with medication analysis was significantly more pro-
nounced among patients with hypertension (p =  0.011) 
and heart failure (p =  0.001) [26]. The results obtained 
with the preliminary version of the tool indicate that the 
application of the tool in the CMR process was effective 
and considered practicable.
The tool was developed on the basis of data obtained by 
means of a literature search on the subject of CMR and 
DRPs, clinical expertise and a Delphi procedure. Experts 
were asked to appraise the initial tool with respect to 
completeness, accuracy and redundancies. A limitation 
of our study was the lack of validation of the CMR tool. 
The CMR tool was tested in a randomized controlled 
study, but further validation is necessary. Another limita-
tion is the rapid change in demographic pattern of dis-
eases, evidence-based therapies and guidelines in the 
different countries. Therefore periodically revising the 
contents of the CMR tool will be necessary. The panel 
of experts did not include a mental health person. Given 
the extent of mental health issues in the elderly, a mental 
health person could give useful suggestions.
Conclusion
In conclusion, we developed a structured, compre-
hensive and practicable tool for pharmacists and 
GPs to perform CMR, including a list of potential 
DRPs in older patients with chronic disease and a 
script for structured patient interviews. Future stud-
ies should address the implementation of this tool in 
daily practice, particularly with respect to electronic 
DRP screening and improving the interaction of elec-
tronic pharmacy and GP information systems in order 
to enhance the efficiency at the evaluation and com-
munication stages. In addition, the effects of using the 
tool in CMR processes on health outcomes and costs 
should be investigated.
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